BACKGROUND: Activation of the mammalian target of rapamycin (mTOR) signaling pathway is thought to be a key driver of tumor growth in Merlin (NF2)-deficient tumors. Everolimus is an oral inhibitor of mTOR complex 1 (mTORC1) with antitumor activity in a variety of cancers. METHODS: We conducted a single-institution, prospective, 2-stage, open-label phase II study to estimate the response rate to everolimus in neurofibromatosis type 2 (NF2) patients with progressive vestibular schwannoma (VS). Ten eligible patients were enrolled, including 2 pediatric patients. Everolimus was administered at a daily dose of 10 mg (adults) or 5 mg/m(2)/day (children <18 y) orally in continuous 28-day courses, for up to 12 courses. Response was assessed every 3 months with MRI, using 3-dimensional volumetric tumor analysis, and audiograms. Nine patients were evaluable for the primary response, defined as ≥15% decrease in VS volume. Hearing response was evaluable as a secondary endpoint in 8 patients. RESULTS: None of the 9 patients with evaluable disease experienced a clinical or MRI response. No objective imaging or hearing responses were observed in stage 1 of the trial, and the study was closed according to predefined stopping rules. CONCLUSION: Everolimus is ineffective for the treatment of progressive VS in NF2 patients. We are currently conducting a pharmacokinetic/pharmacodynamic ("phase 0") study of everolimus in presurgical VS patients to elucidate the biological basis for apparent treatment resistance to mTORC1 inhibition in these tumors.
BACKGROUND: Activation of the mammalian target of rapamycin (mTOR) signaling pathway is thought to be a key driver of tumor growth in Merlin (NF2)-deficient tumors. Everolimus is an oral inhibitor of mTOR complex 1 (mTORC1) with antitumor activity in a variety of cancers. METHODS: We conducted a single-institution, prospective, 2-stage, open-label phase II study to estimate the response rate to everolimus in neurofibromatosis type 2 (NF2) patients with progressive vestibular schwannoma (VS). Ten eligible patients were enrolled, including 2 pediatric patients. Everolimus was administered at a daily dose of 10 mg (adults) or 5 mg/m(2)/day (children <18 y) orally in continuous 28-day courses, for up to 12 courses. Response was assessed every 3 months with MRI, using 3-dimensional volumetric tumor analysis, and audiograms. Nine patients were evaluable for the primary response, defined as ≥15% decrease in VS volume. Hearing response was evaluable as a secondary endpoint in 8 patients. RESULTS: None of the 9 patients with evaluable disease experienced a clinical or MRI response. No objective imaging or hearing responses were observed in stage 1 of the trial, and the study was closed according to predefined stopping rules. CONCLUSION:Everolimus is ineffective for the treatment of progressive VS in NF2patients. We are currently conducting a pharmacokinetic/pharmacodynamic ("phase 0") study of everolimus in presurgical VS patients to elucidate the biological basis for apparent treatment resistance to mTORC1 inhibition in these tumors.
Entities:
Keywords:
everolimus; mammalian target of rapamycin; neurofibromatosis type 2; phase II trial; vestibular schwannoma.
Authors: Jaishri O Blakeley; D Gareth Evans; John Adler; Derald Brackmann; Ruihong Chen; Rosalie E Ferner; C Oliver Hanemann; Gordon Harris; Susan M Huson; Abraham Jacob; Michel Kalamarides; Matthias A Karajannis; Bruce R Korf; Victor-Felix Mautner; Andrea I McClatchey; Harry Miao; Scott R Plotkin; William Slattery; Anat O Stemmer-Rachamimov; D Bradley Welling; Patrick Y Wen; Brigitte Widemann; Kim Hunter-Schaedle; Marco Giovannini Journal: Am J Med Genet A Date: 2011-12-02 Impact factor: 2.802
Authors: Marianne F James; Elizabeth Stivison; Roberta Beauchamp; Sangyeul Han; Hua Li; Margaret R Wallace; James F Gusella; Anat O Stemmer-Rachamimov; Vijaya Ramesh Journal: Mol Cancer Res Date: 2012-03-16 Impact factor: 5.852
Authors: Michael S Dirks; John A Butman; H Jeffrey Kim; Tianxia Wu; Keaton Morgan; Anne P Tran; Russell R Lonser; Ashok R Asthagiri Journal: J Neurosurg Date: 2012-04-13 Impact factor: 5.115
Authors: Matthias A Karajannis; Geneviève Legault; Mari Hagiwara; Marc S Ballas; Krysten Brown; Annette O Nusbaum; Tsivia Hochman; Judith D Goldberg; Kevin M Koch; John G Golfinos; J Thomas Roland; Jeffrey C Allen Journal: Neuro Oncol Date: 2012-07-27 Impact factor: 12.300
Authors: John J Bissler; J Christopher Kingswood; Elżbieta Radzikowska; Bernard A Zonnenberg; Michael Frost; Elena Belousova; Matthias Sauter; Norio Nonomura; Susanne Brakemeier; Petrus J de Vries; Vicky H Whittemore; David Chen; Tarek Sahmoud; Gaurav Shah; Jeremie Lincy; David Lebwohl; Klemens Budde Journal: Lancet Date: 2013-03-09 Impact factor: 79.321
Authors: Daphne L Wang; Kelly B Smith; Sonia Esparza; Fawn A Leigh; Alona Muzikansky; Elyse R Park; Scott R Plotkin Journal: Genet Med Date: 2012-08-09 Impact factor: 8.822
Authors: Marisa A Fuse; Christine T Dinh; Jeremie Vitte; Joanna Kirkpatrick; Thomas Mindos; Stephani Klingeman Plati; Juan I Young; Jie Huang; Annemarie Carlstedt; Maria Clara Franco; Konstantin Brnjos; Jackson Nagamoto; Alejandra M Petrilli; Alicja J Copik; Julia N Soulakova; Olena Bracho; Denise Yan; Rahul Mittal; Rulong Shen; Fred F Telischi; Helen Morrison; Marco Giovannini; Xue-Zhong Liu; Long-Sheng Chang; Cristina Fernandez-Valle Journal: Neuro Oncol Date: 2019-03-18 Impact factor: 12.300